Sun Hopes Cequa’s Nano Formulation Makes Big Impact
Executive Summary
Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?
You may also be interested in...
Ocular’s Dry Eye Drug Fails In Phase II, But It Isn’t Giving Up Yet
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.
Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward
AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.
Bausch + Lomb’s Dry Eye Pivotal Data Pave The Way For Spinout
B+L’s novel therapy for a subset of dry eye disease hits both sign and symptom endpoints in the first of two Phase III studies. The product could add value to a planned spinout.